Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H25N5O4 |
Molecular Weight | 387.4329 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4CCCO4
InChI
InChIKey=VCKUSRYTPJJLNI-UHFFFAOYSA-N
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
Molecular Formula | C19H25N5O4 |
Molecular Weight | 387.4329 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/75140_Terazosin%20Hydrochloride_prntlbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/10503165
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/75140_Terazosin%20Hydrochloride_prntlbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/10503165
Terazosin (marketed as Hytrin or Zayasel) is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of α1-receptors activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23178151
Curator's Comment: Known to be CNS penetrant in rats Human data not available
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2462301 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TERAZOSIN HYDROCHLORIDE Approved Useare used to treat high blood preassure (hypertension); are also used to treat benign prostatic hyperplasia (BPH) in men Launch Date9.5022717E11 |
|||
Primary | TERAZOSIN HYDROCHLORIDE Approved Useare used to treat high blood preassure (hypertension); are also used to treat benign prostatic hyperplasia (BPH) in men Launch Date9.501408E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
48 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1685091 |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERAZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
37 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1685091 |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERAZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
408 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1685091 |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERAZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
418 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1685091 |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERAZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1685091 |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERAZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
9.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1685091 |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERAZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2872802 |
TERAZOSIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p.1169 |
unhealthy n = 14 Health Status: unhealthy Condition: Hypertension Population Size: 14 Sources: Page: p.1169 |
Disc. AE: Dizziness... AEs leading to discontinuation/dose reduction: Dizziness Sources: Page: p.1169 |
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p.903 |
unhealthy n = 37 Health Status: unhealthy Condition: Hypertension Population Size: 37 Sources: Page: p.903 |
Disc. AE: Syncope... AEs leading to discontinuation/dose reduction: Syncope (2.7%) Sources: Page: p.903 |
20 mg 1 times / day multiple, oral MTD Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.9 |
unhealthy Health Status: unhealthy Condition: Benign Prostatic Hyperplasia|Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.9 |
|
10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.6 |
unhealthy Health Status: unhealthy Condition: Benign Prostatic Hyperplasia|Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.6 |
Other AEs: Syncope, Postural hypotension... Other AEs: Syncope Sources: Postural hypotension Priapism https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.6 |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.409 |
unhealthy n = 494 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 494 Sources: Page: p.409 |
Disc. AE: Dizziness, Asthenia... AEs leading to discontinuation/dose reduction: Dizziness (6.7%) Sources: Page: p.409Asthenia (3.8%) Somnolence (2%) Chest pain (1.6%) Headache (1.2%) Dyspnea (1.2%) Prostate carcinoma (1%) |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Disc. AE: Fever, Headache... AEs leading to discontinuation/dose reduction: Fever (0.5%) Sources: Headache (1.1%) Postural hypotension (0.5%) Syncope (0.5%) Nausea (0.5%) Dizziness (2%) Vertigo (0.5%) Dyspnea (0.5%) Blurred vision (0.6%) Amblyopia (0.6%) Urinary tract infection (0.5%) https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Disc. AE: Asthenia, Headache... AEs leading to discontinuation/dose reduction: Asthenia (1.6%) Sources: Headache (1.3%) Palpitations (1.4%) Postural hypotension (0.5%) Syncope (0.5%) Tachycardia (0.6%) Nausea (0.8%) Peripheral edema (0.6%) Dizziness (3.1%) Paresthesia (0.8%) Somnolence (0.6%) Dyspnea (0.9%) Nasal congestion (0.6%) Blurred vision (0.6%) https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | Disc. AE | 80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p.1169 |
unhealthy n = 14 Health Status: unhealthy Condition: Hypertension Population Size: 14 Sources: Page: p.1169 |
Syncope | 2.7% Disc. AE |
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p.903 |
unhealthy n = 37 Health Status: unhealthy Condition: Hypertension Population Size: 37 Sources: Page: p.903 |
Postural hypotension | 10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.6 |
unhealthy Health Status: unhealthy Condition: Benign Prostatic Hyperplasia|Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.6 |
|
Priapism | 10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.6 |
unhealthy Health Status: unhealthy Condition: Benign Prostatic Hyperplasia|Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.6 |
|
Syncope | 10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.6 |
unhealthy Health Status: unhealthy Condition: Benign Prostatic Hyperplasia|Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.6 |
|
Prostate carcinoma | 1% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.409 |
unhealthy n = 494 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 494 Sources: Page: p.409 |
Dyspnea | 1.2% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.409 |
unhealthy n = 494 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 494 Sources: Page: p.409 |
Headache | 1.2% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.409 |
unhealthy n = 494 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 494 Sources: Page: p.409 |
Chest pain | 1.6% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.409 |
unhealthy n = 494 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 494 Sources: Page: p.409 |
Somnolence | 2% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.409 |
unhealthy n = 494 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 494 Sources: Page: p.409 |
Asthenia | 3.8% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.409 |
unhealthy n = 494 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 494 Sources: Page: p.409 |
Dizziness | 6.7% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.409 |
unhealthy n = 494 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 494 Sources: Page: p.409 |
Dyspnea | 0.5% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Fever | 0.5% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Nausea | 0.5% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Postural hypotension | 0.5% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Syncope | 0.5% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Urinary tract infection | 0.5% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Vertigo | 0.5% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Amblyopia | 0.6% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Blurred vision | 0.6% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Headache | 1.1% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Dizziness | 2% Disc. AE |
20 mg 1 times / day multiple, oral (max) Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
unhealthy n = 636 Health Status: unhealthy Condition: Benign Prostatic Hyperplasia Sex: M Population Size: 636 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.12 |
Postural hypotension | 0.5% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Syncope | 0.5% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Blurred vision | 0.6% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Nasal congestion | 0.6% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Peripheral edema | 0.6% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Somnolence | 0.6% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Tachycardia | 0.6% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Nausea | 0.8% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Paresthesia | 0.8% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Dyspnea | 0.9% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Headache | 1.3% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Palpitations | 1.4% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Asthenia | 1.6% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
Dizziness | 3.1% Disc. AE |
40 mg 1 times / day multiple, oral (max) Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
unhealthy n = 859 Health Status: unhealthy Condition: Hypertension Population Size: 859 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf Page: p.16 |
PubMed
Title | Date | PubMed |
---|---|---|
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. | 1998 |
|
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. | 2000 Aug 15 |
|
High-performance liquid chromatographic analysis and pharmacokinetics of terazosin in healthy volunteers. | 2001 |
|
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. | 2001 |
|
Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia. | 2001 |
|
Lower urinary tract symptoms suggestive of benign prostatic obstruction--Triumph: the role of general practice databases. | 2001 |
|
5alpha-reductase inhibitors: what role should they play? | 2001 Dec |
|
Terazosin, doxazosin, and prazosin: current clinical experience. | 2001 Dec |
|
Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia. | 2001 Feb |
|
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome. | 2001 Feb |
|
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. | 2001 Jan |
|
alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. | 2001 Jan |
|
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. | 2001 Jan 1 |
|
Loss of nocturnal dipping of blood pressure and heart rate in obesity-induced hypertension in rabbits. | 2001 Jul 20 |
|
Comparison of prazosin, terazosin and tamsulosin: functional and binding studies in isolated prostatic and vascular human tissues. | 2001 Jun 1 |
|
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations. | 2001 May |
|
Pharmacological blockade of brain alpha1-adrenoceptors as measured by ex vivo [3H]prazosin binding is correlated with behavioral immobility. | 2001 May 25 |
|
Terazosin for benign prostatic hyperplasia. | 2002 |
|
Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia. | 2002 |
|
Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction. | 2002 Apr |
|
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. | 2002 Apr |
|
The use of alpha-adrenoceptor antagonists in lower urinary tract disease. | 2002 Feb |
|
Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. | 2002 Feb |
|
Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs. | 2002 Feb |
|
Prior iontophoresis of saline enhances vasoconstriction to phenylephrine and clonidine in the skin of the human forearm. | 2002 Jul |
|
Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. | 2002 Jun |
|
The efficacy of terazosin for treating benign prostatic hyperplasia: a multicentre clinical trial. | 2002 May |
|
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). | 2002 Nov-Dec |
|
[alpha 1-receptor blockade in therapy of benign prostatic hyperplasia syndrome. Correct dosing for optimal effectiveness]. | 2002 Sep |
|
[Results of monotherapy with terazosin (kornam) in chronic infectious prostatitis patients]. | 2002 Sep-Oct |
|
[Urodynamic criteria of predicting efficacy of therapy with alpha1-adrenergic blockaders in patients with benign prostatic hyperplasia]. | 2002 Sep-Oct |
|
[Comparative evaluation of the efficacy of using terazosin and tamsulosin in patients with benign prostatic hyperplasia]. | 2002 Sep-Oct |
|
[Serum nitric oxide and D-dimer before and after administering antihypertensive drugs in essential hypertension]. | 2003 Aug |
|
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. | 2003 Aug |
|
Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. | 2003 Feb |
|
Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in conscious rats with bladder outlet obstruction. | 2003 Jul |
|
Is terazosin helpful in chronic prostatitis? | 2003 Jun |
|
Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. | 2003 May |
|
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. | 2003 May 19 |
|
Review: terazosin improves urologic symptoms in benign prostatic hyperplasia. | 2003 May-Jun |
|
Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. | 2003 Nov |
|
[Pharmacologic treatment of benign prostatic hyperplasia]. | 2003 Sep 14 |
|
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). | 2004 Feb 23 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/terazosin.html
for Hypertension:
Initial dose: 1 mg orally once a day at bedtime; Maintenance dose: 1-5 mg orally once a day. Maximum dose: 20 mg per day.
Usual Adult Dose for Benign Prostatic Hyperplasia:
Initial dose: 1 mg orally once a day at bedtime. Maintenance dose: Increased in a stepwise fashion to 2 mg, 5 mg, or 10 mg once a day to achieve desired improvement of symptoms.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25383758
Curator's Comment: TZ (terazosin) has a new protein target, Pgk1 (phosphoglycerate kinase 1), and reveal its corresponding biological effect. As a clinical drug, TZ may be quickly translated into treatments for diseases including stroke and sepsis.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:38:01 UTC 2023
by
admin
on
Wed Jul 05 23:38:01 UTC 2023
|
Record UNII |
8L5014XET7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QG04CA03
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
||
|
WHO-ATC |
G04CA03
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
||
|
NDF-RT |
N0000000099
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
||
|
LIVERTOX |
NBK548096
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
||
|
NDF-RT |
N0000175553
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
37798
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | RxNorm | ||
|
7302
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
100000082702
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
3584
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
9445
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
CHEMBL611
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
8L5014XET7
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
DB01162
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
C61964
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
4843
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
DTXSID3023639
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
C041226
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
SUB10907MIG
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
8L5014XET7
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
5401
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
M10567
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | Merck Index | ||
|
TERAZOSIN
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
63590-64-7
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY | |||
|
Terazosin
Created by
admin on Wed Jul 05 23:38:01 UTC 2023 , Edited by admin on Wed Jul 05 23:38:01 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||